The transcription factor C/EBPα is a critical mediator of myeloid differentiation and is often functionally impaired in acute myeloid leukemia. Recent results suggest that oncogenic FLT3 activity disrupts wild type C/EBPα function via phosphorylation on serine 21. Despite the apparent role of pS21 as a negative regulator of C/EBPα transcription activity, the mechanism by which phosphorylation tips the balance between transcriptionally competent and inhibited forms remains unresolved. Here we use immunoaffinity purification combined with quantitative mass spectrometry to delineate proteins associated with C/EBPα on chromatin. We identify DEK, a protein with genetic links to leukemia, as a member of C/EBPα complexes, and demonstrate that this association is disrupted by serine 21 phosphorylation. We confirm that DEK is specifically recruited to chromatin with C/EBPα to enhance GCSFR3 promoter activation. In addition we demonstrate that genetic depletion of DEK reduces the ability of C/EBPα to drive expression of granulocytic target genes in vitro, and disrupts G-CSFmediated granulocytic differentiation of fresh human bone marrow derived CD34+ cells. These data suggest that C/EBPα and DEK coordinately activate myeloid gene expression and that serine 21 phosphorylation on wild-type C/EBPα mediates protein interactions that regulate the differentiation capacity of hematopoietic progenitors.
Introduction
C/EBPα is the founding member of the C/EBP family of transcription factors, whose constituents share a conserved leucine-zipper dimerization domain. 1 Although C/EBPα participates in the development of many tissues, the phenotype of knock-out mice best illustrates the basic requirement of C/EBPα for life 2 along with its central role in hematopoiesis in general, 3 and granulopoiesis in particular. 4 Fetal livers of C/EBPα null mice are hyperproliferative and exhibit limited capacity for the development of bipotent granulocyte/monocyte progeny and terminally differentiated granulocytes. 5 Similarly, conditional disruption of C/EBPα expression disrupts the formation of granulocytes and leads to a concomitant increase in self-renewal of hematopoietic stem cells (HSC). In addition, studies utilizing ectopic expression illustrate that C/EBPα is a key molecular determinant in myeloid lineage commitment. 4, 6, 7 C/EBPα drives myeloid differentiation through two, distinct roles (reviewed by Friedman, et al. 8 ): (a) activation of myeloid target genes including: CEBPE, GCSFR3,
MPO, ELA, LF, mim-1, miR34a; and (b) inhibition of cell cycle through interactions
with regulatory proteins such as: CDK2/4, p21, E2F, and pRb family members. In the context of granulopoiesis, the anti-proliferative role of C/EBPα has been well described, 9 while recent studies demonstrated that various transcription co-regulatory proteins, including CBP/p300, 10 c-Jun, 11 histone acetyltransferase TIP60, 12 and Max, 13 participate with C/EBPα to mediate myeloid differentiation. Although recent studies have focused on C/EBPα-mediated gene activation in hematopoietic cells, along with its role in chromatin structure, 14 the underlying molecular mechanisms remain largely unresolved.
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The observation that C/EBPα is required for proper regulation of the myeloid compartment suggests that loss-of-function may result in differentiation arrest.
Consistent with this hypothesis, the bone marrow of adult C/EBPα -/-mice contains myeloblasts, similar to the phenotype observed in human acute myeloid leukemia (AML). 15 Indeed, an increasing body of evidence suggests that impaired function of C/EBPα leads to accumulation of myeloid progenitors and eventually leukemic blasts. 16, 17 In hematopoietic malignancies, genetic lesions or dominant negative interactions represent the most common mechanisms for disruption of C/EBPα activity.
For example somatic mutations result in expression of C/EBPα proteins that exhibit diminished DNA binding, while mutations at the 5' end of the gene result in translation from an alternative start site and expression of an N-terminally truncated protein (C/EBPα p30) product that functions as a dominant negative with respect to the wildtype protein. 18 In a subset of AML patients who do not harbor C/EBPα mutations, overexpression of TRIB2 is correlated with hypermethylation of the CEBPα promoter region; 19 moreover, TRIB2 inactivates C/EBPα and induces leukemia in mice. 20 Finally, translational and transcriptional repression in the context of oncogenic BCR-ABL and AML1-ETO translocation products (reviewed by Pabst et al. 17 ), respectfully, lead to diminished expression of C/EBPα and inhibition of granulopoiesis.
Interestingly, oncogenic FLT3-ITD mediates phosphorylation of serine 21 (pS21) on C/EBPα in model cell lines, as well as AML blasts, and disrupts granulocytic differentiation in vitro. 21 The link between FLT3 and C/EBPα is particularly intriguing
given that (a) multiple oncogenic events are required for a highly penetrant AML
For personal use only. on . by guest www.bloodjournal.org From phenotype and (b) aberrant expression of FLT3 or genetic mutations that confer constitutive activity to this kinase represent the most frequent molecular abnormalities in AML. 22 In addition S21 is differentially phosphorylated in lineage depleted mouse progenitor cells by downstream mediators of monocyte (M-CSF) and granulocyte (G-CSF) pathways, respectively; moreover, targeted inhibition of effectors in these pathways (MEK and SHP2, respectively) significantly diminishes pS21. 23 These results, combined with evidence that pS21 does not appreciably alter C/EBPα affinity for DNA, 24 led us to hypothesize that protein-protein interactions mediated by phosphorylation may play a critical role in regulation of myeloid gene expression and ultimately granulocytic differentiation.
The protein DEK was originally identified as a fusion with the CAN/NUP214 nucleoporin in a subset of AML patients who harbored the t(6;9)(p23;q64) translocation.
25
DEK-CAN induces leukemia in the hematopoietic stem cell compartment of mice, specifically from long term multipotent progenitors.
26
Overexpression of DEK mRNA has been reported in AML, and also in a variety of solid tumors, including: melanoma, glioblastoma, and retinoblastoma, along with small cell lung, cervical, and bladder cancers (reviewed by Riveiro-Falkenbach and Soengas 27 ).
Inactivation of DEK in mouse models results in reduced papilloma formation. The coordinate activity of DEK with HPV-E6/7 and HRAS in the formation and proliferation of keratinocyte tumors 28 further illustrates the oncogenic capacity of this gene.
Interestingly, nearly 50% of patients with a DEK-CAN translocation are also heterozygous for FLT3-ITD, a mutation that confers constitutive kinase activity and is correlated with poor clinical outcomes in AML. 29 The role of DEK in transcription varies 
Results

DEK interacts with C/EBPα on chromatin as a function of S21 phosphorylation.
Given the role of C/EBPα in cell cycle arrest we reasoned that a successful proteomics screen of C/EBPα protein complexes would require (a) an inducible and (b) affinity tagged form of C/EBPα. We generated a tetracycline inducible, C-terminally tagged form of C/EBPα (C/EBPα-FLAG/HA) in MOLM-14 cells, a line originally derived from the peripheral blood of a patient with AML and characterized by mutation FLT3-ITD.
Importantly, we chose MOLM-14 cells for our model system because they recapitulate the reported molecular links between oncogenic FLT3 and C/EBPα. 21 Figure 1A
demonstrates that C/EBPα-FLAG/HA expression was comparable to the level of endogenous protein in the chromatin fraction. Furthermore, treatment with a small molecule MEK inhibitor did not affect expression of C/EBPα but did reduce S21 phosphorylation ( Figure 1B) . We also verified the DNA binding activity of C/EBPα- Table S1 ). In addition we detected many proteins previously reported to interact with C/EBPα, including: PARP1, 34 SMARCC1, SMARCC2, 35 Jun-D, 11 CREB1, 36 UBF-1, 37 and C/EBPβ. 38 More importantly we observed that participation of several proteins in the C/EBPα complex was dependent on the phosphorylation status of S21 (Table 1) 
C/EBPα and DEK co-localize in the nucleus.
To provide further evidence for co-localization of C/EBPα and DEK, we used a proximity ligation assay (PLA). First we carried out shRNA-mediated protein depletion with lentiviral particles containing either a control vector (KH1) or a sequence targeting DEK (shDEK1) in myeloid K562 cells that expressed either wild type C/EBPα fused to the estrogen receptor ligand binding domain (WT-ER) 24 or a control (ER domain alone).
The WT-ER cells provide a useful model system to study the dynamics of C/EBPα dependent granulocytic differentiation, 24, 39 as they respond to β -estradiol treatment by nuclear translocation of C/EBPα-ER protein followed by up-regulation of C/EBPα target 
DEK-C/EBPα interaction coordinately regulates activation of GCSFR3.
Having established that a bona fide and phosphorylation-dependent interaction existed between DEK-C/EBPα, we next asked whether DEK played a functional role in the activation of GCSFR3, a myeloid target gene of C/EBPα. We utilized a luciferase reporter construct containing the TK minimal promoter with tetramers of either a wild type, or mutated C/EBPα binding site from the human GCSFR3 promoter 18 . These experiments were performed in 293T cells that express endogenous DEK protein but have no detectable C/EBPα. Figure 3A shows that DEK activated the wild type C/EBPα-dependent reporter in a dose-dependent manner only when expressed with
For personal use only. on . by guest www.bloodjournal.org From either the C/EBPα WT or S21A phosphonull mutant. Conversely neither the individual nor combined expression of C/EBPα and DEK was sufficient to drive luciferase activity of the mutant reporter construct. To explore the possibility that DEK has affinity to regions of the GCSFR3 promoter that neighbor the C/EBPα binding site, we next utilized luciferase constructs that contained a short sequence (+74/-67) derived from the native GCSFR3 promoter region, or the corresponding sequence with a mutated C/EBPα binding site 40 . Again we observed a dose-dependent response to DEK only in presence of WT and S21A C/EBPα expression vectors ( Figure 3B ), suggesting that DEK cooperates with dephosphorylated C/EBPα to augment transactivation capacity.
We next used chromatin immunoprecipitation (ChIP) in K562 cells expressing C/EBPα mutants (WT-ER, S21A-ER and S21D-ER) 24 or a negative control (ER) to determine whether DEK participated in C/EBPα transcription complexes at endogenous GCSFR3 promoters. DEK immunoprecipitation followed by PCR with primers to the GCSFR3 promoter region 12 revealed that this protein bound to DNA specifically and in close proximity to the canonical C/EBPα binding site on GCSFR3 ( Figure 3C ).
Significantly, binding of DEK to the GCSFR3 promoter region was in direct response to C/EBPα nuclear localization (via β -estradiol stimulation) as evidenced by lack of signal prior to β -estradiol stimulation. We observed increased binding of DEK to the GCSFR3 promoter region in the presence of C/EBPα S21A-ER. Conversely there was no binding of DEK to the GAPDH promoter region under any of the conditions tested. We observed similar results for ChIP analysis performed with an antibody to C/EBPα ( Figure 3D ).
The kinetic profiles in Figures 3A and B are consistent with co-localization of DEK and Figure 4A ). Depletion of DEK in K562 ER cells did not affect GCSFR3 mRNA levels ( Figure 4B ). Consistent with our luciferase data, we observed that endogenous DEK (KH1) in the presence of WT (WT-ER) or dephosphorylated (S21A-ER) C/EBPα drove robust, time dependent expression of GCSFR3 mRNA upon C/EBPα nuclear translocation. Significantly, depletion of DEK reduced C/EBPα-mediated GCSFR3 expression in WT-ER and S21A-ER cells. In contrast we observed that GCSFR3 mRNA expression was low and largely independent of both DEK and the phosphomimetic form (S21D-ER) of C/EBPα. CEBPE mRNA levels were similarly dependent upon the co-expression of DEK with either WT or S21A-ER C/EBPα, albeit with somewhat different kinetics ( Figure 4C ). These data provide further support for the hypothesis that DEK is a co-activator of C/EBPα-mediated transcription. The affinity of These data confirmed expression of C/EBPα and DEK during differentiation and suggest that our ex-vivo model recapitulates granulopoiesis as defined by coordinate expression of specific surface markers. To
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We observed significant reduction in DEK protein levels using two different lentiviral constructs ( Figure 5A,B) . We next assessed the role of DEK in myeloid colony formation. Figure 5C Table   S4 ). These data illustrate that DEK does not play a major role in CD34+ cell cycle regulation. In summary, our findings suggest that C/EBPα-DEK complexes couple GCSFR3-mediated signaling to the expression of specific genes within the myeloid differentiation program. 
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Cancer cell lines and primary CD34+ myeloid progenitors are valuable tools for discovery and interrogation of functionally relevant protein interactions; however, biochemical validation of these molecular pathways in primary tumors is complicated by cellular and genomic heterogeneity. With these caveats in mind we probed primary patient AML blasts genotyped as FLT3-WT or -ITD for expression of DEK and C/EBPα, in addition to serine 21 phosphorylation status ( Figure 6 ). We detected DEK protein in all AML samples suggesting that expression of DEK in primary blasts is independent of FLT3 activity. Expression of C/EBPα was detectable in 13 out of 14 AML samples, while phosphorylation on S21 was observed in 8 out of 14 patient samples. These data are consistent with our hypothesis that FLT3-mediated phosphorylation on serine 21 of C/EBPα disrupts protein interactions required for competent gene activation and contributes to differentiation arrest in AML.
Discussion
Myeloid cell fate is coordinately regulated by a number of transcription factors, including C/EBPα, PARP1, GATA1, PU.1, C-MYB, and AML1/CBFβ. C/EBPα functions as a primary molecular determinant of granulopoiesis and mediates differentiation of granulocyte-monocyte progenitors through interactions with a diverse set of chromatin modifiers and transcription factors that collectively activate (CBP/p300, 10 c-Jun, 11 histone acetyltransferase TIP60, 12 regulation it is plausible that co-activators are required to ensure maximal activation of specific target genes. Collectively, our results suggest that DEK is a co-regulator that is required for fully competent C/EBPα-mediated GCSFR3 transcription.
To define the role of DEK in granulocyte lineage commitment we performed biochemical assays in a model system that encompassed (a) endogenous protein levels, Previous studies demonstrated that expression of wild type C/EBPα or the S21A mutant induced CD15 in CD34+ cells. 7, 48 Our data demonstrate that depletion of DEK disrupts G-CSF-mediated expression of CD15 and terminal differentiation in CD34+
progenitors. These results suggest that DEK participates in a common pathway, For 
